immunoprecise.com - IPA Company Long-Term Liabilities

ImmunoPrecise Antibodies Ltd. (IPA) - corporate logo

The market price on GURU.Markets, as confirmed by the chart, recorded long-term debt at 0.01. ImmunoPrecise Antibodies (IPA) merges IT and genetics, attracting visionaries through academic freedom and stock options. The business is based on AI platforms that automate the search for gene sequences. Process stability is guaranteed by streamlined air transport of biomaterials under strict temperature control.

IPA ImmunoPrecise Antibodies Ltd Company Long-Term Liabilities (07/04/2022 - 09/04/2025)

Financial and market metric breakdowns for ImmunoPrecise Antibodies Ltd. (IPA)

- price and consensus price forecast:
Market Chart ImmunoPrecise Antibodies Ltd|IPA - Price Target Chart
- market capitalization data:
Market Valuation ImmunoPrecise Antibodies|IPA - Total Company Value
- book capitalization data:
Accounting Value per Share ImmunoPrecise Antibodies|IPA - Company Net Assets|Market Capitalization to Book Value Ratio immunoprecise.com|IPA - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio ImmunoPrecise Antibodies|IPA - Long-Term Debt to Equity|Current Liabilities to Capital ImmunoPrecise Antibodies Ltd|IPA - Company Debts|Debts to Book Capitalization Ratio ImmunoPrecise Antibodies|IPA - Company Long-Term Debt|Company Short-Term Loans and Borrowings ImmunoPrecise Antibodies
Basic company analysis:ImmunoPrecise Antibodies (IPA)
Manufactured products of immunoprecise.com

Institutional investors are assessing the long-term debt load of ImmunoPrecise Antibodies (IPA) to determine the issuer's financial stability. This indicator aggregates obligations with maturities exceeding one year, reflecting the total volume of the corporation's long-term loans and borrowings. The trend of this metric allows for the identification of hidden debt patterns prior to the release of quarterly reports. For an AI-driven antibody discovery business, moderate debt facilitates the scaling of the client base. Monitoring this parameter confirms the asset's reliability and the absence of default risks.

Analysis of competing companies

Tempus Labs - Long-Term Debt Volume|QGEN: Company Long-Term Debt|IONS: Company Long-Term Liabilities|RGEN (Repligen Corp.) - Company Long-Term Debt|Company Long-Term Liabilities Avidity Corp|CRSP (CRISPR Therapeutics AG) - Company Long-Term Liabilities|Company Long-Term Debts WGS|Company Long-Term Debt Ultragenyx RARE|Company Long-Term Indebtedness BEAM (Beam Therapeutics Inc)|SRPT: Company Long-Term Debt|Twist Bioscience Corp - Long-Term Debt|Company Long-Term Debt 10x Genomics, Inc.|NTLA: Long-Term Liabilities|Company Long-Term Debt Stoke Therapeutics, Inc. STOK|BioLife Solutions Inc (BLFS) - Company Long-Term Loans and Borrowings|Company Long-Term Debts WVE (Wave Life Sciences Corp)|Long-Term Debt Maze Therapeutics Corp|Company Long-Term Debts SION (Sionna Therapeutics Inc)|Company Long-Term Liabilities primemedicine.com (PRME)|Company Long-Term Debts TSHA|uniQure NV - Long-Term Debt Volume|Company Long-Term Debt MGTX (MeiraGTx PLC)|RGNX - Long-Term Debt Volume|Company Long-Term Debts SLDB|Long-Term Debt ocugen.com|PACB - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings Benitec Biopharma Inc|Company Long-Term Debts DSGN|Company Long-Term Debts RCKT (Rocket Corp)|FDMT - Company Long-Term Debt|LXEO - Company Long-Term Indebtedness|Company Long-Term Liabilities Korro Bio, Inc KRRO|EDIT - Amount of Long-Term Liabilities|Silence Therapeutics Inc. - Company Long-Term Debts|ProQR Therapeutics (PRQR) - Long-Term Debt Volume|Company Long-Term Debts Codexis Inc|Company Long-Term Debt SGMO|Nautilus Biotechnology - Company Long-Term Debt|Long-Term Debt Metagenomi Inc. (MGX)|DTIL - Company Long-Term Debts|Company Long-Term Indebtedness Generation Bio Co GBIO|Company Long-Term Debts BOLD (Boundless Bio, Inc.)|XCUR - Long-Term Debt Volume|Company Long-Term Debts IMNN|PHIO (Phio Pharmaceuticals Corp.) - Long-Term Debt|MBIO: Company Long-Term Debt|Long-Term Debt Volume TransCode|BNGO (Bionano Genomics, Inc.) - Company Long-Term Debts|Long-Term Debt Volume APDN (adnas.com)|bluebird bio (BLUE) - Company Long-Term Debt|Long-Term Liabilities Omega Therapeutics Inc OMGA|Singular Genomics Systems Inc - Company Long-Term Debts|RGLS - Company Long-Term Debts|Company Long-Term Debts Syros Pharmaceuticals|TBIO (telesisbio.com) - Company Long-Term Indebtedness|Company Long-Term Debt TRACON Pharmaceuticals, Inc. (TCON)|Company Long-Term Indebtedness Unity Biotechnology Inc.